Ziopharm to Participate in Upcoming January Conferences

Rhea-AI Summary

BOSTON, Dec. 23, 2020 – Ziopharm Oncology (Nasdaq: ZIOP) announced that CEO Laurence Cooper will participate in the H.C. Wainwright Bioconnect 2021 Conference on January 11, 2021, and deliver a corporate overview at the 39th Annual J.P. Morgan Healthcare Conference on January 14, 2021. The H.C. Wainwright event starts at 6:00 am ET, while the J.P. Morgan Conference begins at 8:20 am ET. Webcast presentations will be available via the Investors section of the Ziopharm website.

BOSTON, Dec. 23, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or “the Company”) (Nasdaq: ZIOP), today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer of Ziopharm, is scheduled to participate in a fireside chat at the H.C. Wainwright Bioconnect 2021 Conference and will deliver a corporate overview at the 39^th Annual J.P. Morgan Healthcare Conference.

H.C. Wainwright Bioconnect 2021 Conference Date: Monday, January 11, 2021 Time: 6:00 am ET (access to on demand webcast begins) 39th Annual J.P. Morgan Healthcare Conference Date: Thursday, January 14, 2021 Time: 8:20 am ET

To access the webcast presentations, or the subsequent archived recordings, please visit the “Investors” section of the Ziopharm website at www.ziopharm.com.

About Ziopharm Oncology, Inc.
Ziopharm is developing non-viral and cytokine-driven cell and gene therapies that weaponize the body’s immune system to treat the millions of people globally diagnosed with a solid tumor each year. With its multiplatform approach, Ziopharm is at the forefront of immuno-oncology with a goal to treat any type of solid tumor. Ziopharm’s pipeline is built for commercially scalable, cost effective T-cell receptor T-cell therapies based on its non-viral Sleeping Beauty gene transfer platform, a precisely controlled IL-12 gene therapy, and rapidly manufactured Sleeping Beauty-enabled CD19-specific CAR-T program. The Company has clinical and strategic partnerships with the National Cancer Institute, The University of Texas MD Anderson Cancer Center and others. For more information, please visit www.ziopharm.com.

Investor Relations Contacts:
Adam D. Levy, PhD, MBA
EVP, Investor Relations and Corporate Communications
(508) 552-9255
alevy@ziopharm.com

Media Relations Contact:
LifeSci Communications:
Patrick Bursey
T: 646.876.4932
E: pbursey@lifescicomms.com

FAQ

When will ZIOP CEO Laurence Cooper speak at the H.C. Wainwright Bioconnect 2021 Conference?

Laurence Cooper will speak at the H.C. Wainwright Bioconnect 2021 Conference on January 11, 2021, at 6:00 am ET.

What is the date and time for Ziopharm's overview at the J.P. Morgan Healthcare Conference?

Ziopharm's corporate overview will be presented at the 39th Annual J.P. Morgan Healthcare Conference on January 14, 2021, at 8:20 am ET.

How can I access the webcasts for Ziopharm's conference presentations?

The webcasts for Ziopharm's conference presentations can be accessed through the Investors section of their website.

What type of therapies is Ziopharm developing?

Ziopharm is developing non-viral and cytokine-driven cell and gene therapies targeting solid tumors.

What partnerships does Ziopharm have?

Ziopharm has clinical and strategic partnerships with the National Cancer Institute and The University of Texas MD Anderson Cancer Center.